L&T Technology Services just announced something that sounds straight out of science fiction: a digital twin of your lungs. But this isn't some futuristic gimmick—it's a next-generation AI platform designed to help doctors diagnose and treat respiratory diseases more effectively.
The platform, unveiled Monday, leverages L&T's expertise in platform engineering, connected health, advanced imaging, and AI diagnostics. Running on Nvidia's (NVDA) accelerated computing technology, it promises scalable, low-latency solutions that boost diagnostic accuracy and expand access for healthcare providers.
L&T Technology Services plans to showcase the platform at the Radiological Society of North America (RSNA) 2025 conference.
How Digital Twins Work In Medicine
Here's what makes this interesting: The system integrates with CT imaging and uses deep learning to create a 3D digital twin of a patient's lungs. Think of it as a living, breathing model that clinicians can manipulate and explore.
With support from Nvidia Medical Open Network for AI (MONAI) for medical image segmentation and Nvidia TensorRT for efficient AI inference, doctors can visualize anatomy interactively, plan procedures, and navigate bronchoscopies with much greater precision than traditional methods allow.
By converting static scans into dynamic models that evolve with patient health, L&T Technology Services is applying its medical imaging and navigation expertise to support improved treatment planning for lung cancer, chronic obstructive pulmonary disease (COPD), and infectious diseases.
Nvidia's Healthcare Ambitions
This partnership highlights how Nvidia is rapidly expanding its footprint in healthcare AI, moving far beyond its gaming and graphics processing unit roots.
At JP Morgan's Healthcare Conference, analyst Harlan Sur said Nvidia is positioned to capitalize on soaring demand for automation and AI in hospitals. The company is rolling out AI "digital health agents," including delivery robots and generative AI tools for clinical communication, to help address a projected shortage of up to 20 million healthcare workers.
Partnerships with firms like Intrivo and Abridge are already putting these technologies into real-world use.
Sur also pointed to Nvidia's datacenter platforms—Omniverse, Cosmos and DGX Cloud—which are accelerating AI adoption in medicine through flexible deployment options. He expects Nvidia's healthcare business to generate about $1 billion in annual recurring revenue by fiscal 2026.
Nvidia continues to embed AI across drug discovery, robotic surgery and genomics through new collaborations with Iqvia and Illumina, a strategy Sur said strengthens its push to lead the healthcare AI market.
If his projections prove out, healthcare could become Nvidia's next billion-dollar frontier.
NVDA Price Action: Nvidia shares were down 1.76% at $173.88 during premarket trading on Friday.
